Analysts from Oppenheimer raise Nurix Therapeutics' price target to $30 and maintain a "Moderate Buy" rating.

Nurix Therapeutics (NASDAQ: NRIX), a clinical-stage biopharmaceutical firm, has received positive ratings from multiple analysts, including Oppenheimer, which raised its price target to $30.00. The stock, currently at $23.33, has a market cap of $1.15 billion. Analysts generally rate it as a "Moderate Buy" with a consensus target of $27.00. Recent institutional investments indicate growing confidence in the company’s cancer therapies.